Using Nanobodies to Improve CAR T-Cell Therapy
Researchers at Boston Children’s Hospital and MIT have recently been able to show that mini-antibodies called nanobodies – previously discovered more than 20 years ago – may be able to resolve an issue in the cancer field: making chimeric antigen receptor (CAR) T-cell therapies functional in solid tumors. Their research was published in the journal